Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Committee will meet jointly with Pharmaceutical Science Advisory Committee's Drug Safety & Risk Management Subcommittee April 22, according to tentative advisory committee meeting dates posted on FDA's Web site Feb. 28. Although no agenda has been formally announced, acetaminophen and liver toxicity could be topic for discussion (1"The Tan Sheet" Feb. 18, 2002, p. 3). Additional NDAC meeting dates are April 23, June 21...

You may also be interested in...

Acetaminophen Toxicity Headed To NDAC, New FDA Drug Safety Group

Potential liver toxicity risks from acetaminophen use are likely to be among the topics at the inaugural meeting of FDA's Drug Safety & Risk Management Subcommittee

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts